{"ticker": {"uuid": "6d245a59-aaf2-49c2-b017-4ec0def04928", "symbol": "ORKA", "name": "Oruka Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5Gd0pTdnBBVXZ1eXhxeklJYmJLaTFGZDRaeUlBNmxLUTFmNm5nQV9rcDRtR0lLaHQtT2taUklmajlHM05GekRKeGcxdnJ5OF9aNHc?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-18T00:36:00+00:00", "published_display": "18 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdDZLMUZzM1ViXzJfUWU2LXVUNHIyd0l0Rkc1YXBOc1NnajNGVEVvQTBXWDdVemhIWElZcWpzNDEzdDNvWE1BTmZQVUMxdENwWGdrbE5iWnJ0aGlNeFc2NmpDTU1XelVsREY5U1pLUS1id25HRUtmc1R0NEQ0Vko1eU5Vanc4RXgyUVlJYkJPMkFKcUdPN0RpckYyVTJZektf?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T14:51:00+00:00", "published_display": "17 Jul 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Oruka Therapeutics Inc For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPY29tYVZyT0FXejJ5LU1nWWptU2NGNFh4UnFybDc3aU9Bb2MxTEZKS0Q2bUpFdkdDODlEQXBob2FvVm1OVzdUMmV2UjRBVG9wZnlCMU82a19GNGtlSUJ5b0hfa28yLUVfWElia1ZqQUZXOVR1SFpqNGNIWXR5UnFWT2sxN3pNLTZ4S3ZiUlFQOHdySEtsSDNwVWg3TjZoaGJNQ3lZRg?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T00:52:17+00:00", "published_display": "16 Jul 2026 00:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPY0pYZlQ0UzV1V3Jza3hzeUc5cTZCeERmVVVuWDRzdS1sNGpmT3NTUEx0ZExLbUIyMjhNYmgtSnJNdi11Qk9uYzVTRWhlYTRBTW1TbGRkaVhZWjdNSEVzbGx2VFlKRjJ5WFRkRUJfYnBGRjdFb2JPLWFMNllDUm9YZ1dWQUJUSk9aRXpZOUg0SnM0aTQ1aExpNWc4YWJqaXhRRURQLTdqWF9Oc1FwV2EzSWZuTUV6eFJSU3BGTmVyc2YxenFL?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T23:47:40+00:00", "published_display": "15 Jul 2026 23:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oruka-therapeutics-insider-sold-shares-212226470.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:22:26+00:00", "published_display": "13 Jul 2026 21:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How Investors May Respond To Oruka Therapeutics (ORKA) Russell Index Shift Toward Small-Cap Growth Benchmarks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T01:05:46+00:00", "published_display": "10 Jul 2026 01:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oruka-therapeutics-insider-sold-shares-082527388.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:25:27+00:00", "published_display": "02 Jul 2026 08:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/h-c-wainwright-keeps-buy-212333523.html", "source_name": "Insider Monkey", "published_at": "2026-07-01T21:23:33+00:00", "published_display": "01 Jul 2026 21:23", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/oruka-therapeutics-h2-orka-001-152348961.html", "source_name": "MT Newswires", "published_at": "2026-07-01T15:23:48+00:00", "published_display": "01 Jul 2026 15:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on Oruka Therapeutics to $130 From $100, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-oruka-144342183.html", "source_name": "MT Newswires", "published_at": "2026-07-01T14:43:42+00:00", "published_display": "01 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPVm9fWkpWZlNHU2ozLUJwcU1NamYtRkVjb1RvMktGUXBaN0hSNVRPZ0Q4M2NpeGNucGpQakRxM0w3Yng5MmpzdkNnanBqTjVSellBb0pocVJqQ0tDa1RsQjFPV0xwMHdjQkVjMWtiaDVxakFaRXkteVZ5c3hsUHBTWVVHTzhMTDlNRkdScmJ1S1RORWFTRjhIN3R4ZnNjZHp4ZXdRUElVTHVrZFhySVpFRVl3ekg4aFlCWFBXclFQemRCWnh5Z2lpeUhDTQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/650f4e3a-936a-39f2-bc9a-a6fc1616bb65/oruka-therapeutics%27-head-of.html", "source_name": "Motley Fool", "published_at": "2026-06-24T21:44:01+00:00", "published_display": "24 Jun 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Oruka Therapeutics Inc For: 22 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOREo2aHFKSEhjSzNFX2tKZVI4WFhvVXprNUZhNEpDa3RhcFRiU0wxMjZKSzVaeWpZbmZQWDdYME9CLUtvTjcyM1BSWENnS3ctNF9DQUp0WmRqek5pdF9zalpPdi16T2hPZjdGXy1UT3JSYlNMRnJfNVcxeG14ZXBNVDIwZjA4a0dJU3c1US1ReG9ralFQOWdkZnhNclZrR1IyN1hmQQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics SVP Arjun Agarwal sells $128,468 in ORKA stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOZDE0cldyV003Mk5LLXBuYldWOFFWbVZnSm5Uek1qTWppQmVIMUs0cEtaQzB5dDU4eFgzZHdocEZLYVBNT1FybzZabzhmSlJJc2NzMUU1bjJHazhtYXRJU1dZM0FjMVAzaWJOZldWYzdyelJac3RSTHQxTThIQkk4WFVKVEZBMTVQRElTZnlfYTY0ajFoZ3lsSW1YeWsxTDQzMnd5LXRsd1VPN0p3OTI2aVZDS3N4ZnY0NExDOHNiVG41cEpyRFJn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Arjun Agarwal Sells Shares of Oruka Therapeutics I", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPOHhldll2T1l4Ym9zWkhtQi1ET2huWU9zbWFiUkxGRUJvd2FOVzlvVWJUeUN1N3dCS0p5c0Y2bEFsbWlicEs0WFJaVlRBb0V3MllfNnZka29vQ0JrMkw0akFva2o0NV9wNVpUOGplejhQdzZ5UzZtY0VuVFd0dTRQeGFtV2U4cUdWTzI5dHcwdWhNeGNESnRDREMtNFRid0YyOHRWYmhPNTFOTHo3VzNwOUJpdlhmYlJxTEg5M1I5YkxfNGxIblBSRDhJTTE4TjBOZUw0OHRfdE9yT1NSZmw5aU9zYw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSnJXLW05bjhaNFNtZTExWmptRkktcGxIblZVenpyekpQYXo5Rm9mdlNYNjZScUZ3ZjBYNmFDY2tzMXVrUnlIVU1EcEpFY04zSGNuNU9tQlVvTDNNaDdHMHhzYjRNMFpFRENPeXVaUEZuTDkzNFRsVU9QWWpPalZZRFNiM2MwY2FMV25TUHRoUDFfa3BqajlibVl0a1NLWGJINHpN?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPRkEyYXBaUnhGbi1lWGZUQ2VpQkEwMEhjRUNZT2NJdzBsNXJGSFFvVnhxMEh6Vll2S0lJN0R4ZEpuYllXWUppUHUyRnNVMjZkTFhaMWpfZ3FHZWpuNzNmNnRuUVZscjJNaFBwenEzQ2ZVQm9iM1lfYmNSM2RGd2VTZjN3Y1AxRC1faEJDSXdFbHBhUzY2R21oRldrWmhxaEpT?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oruka Therapeutics Announces Closing of Merger with ARCA", "summary": "Oruka Therapeutics announced the completion of its merger with ARCA biopharma and a $275 million private placement. The combined company, now trading on Nasdaq under \"ORKA\", aims to advance pipeline programs ORKA-001 and ORKA-002 for chronic skin diseases. Dr. Samarth Kulkarni ha", "url": "https://www.globenewswire.com/news-release/2024/09/03/2939515/0/en/oruka-therapeutics-announces-closing-of-merger-with-arca-biopharma-and-previously-announced-private-placement-of-275-million.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T19:09:58", "published_display": "13 May 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOdnRPaC1McTZUT1oyVDd1TWlmV3RlZlhRMHZiZkpYZUgwS2pBYmZjcjk2THV2SlItT1VHTDVTWWNJYmpQaGVhREMzaDh3cnZrQkJpbVJRUU1SMEpPN1FyMDlJbWE1XzJaUGVtWWNBQ2lsTWdNckFaaTFabzFCWGpXQ3ZWWksxY0hVZHJaWEpWcDdtN1BBb2xWcDh6NkFSdmJkR3ZGdmFMbm5MWnZRVGJPU2pMSlg5SGZtc1d1YzBBc2dYWTh0LTZzOGhvSDhEX3F6WWtSWGVjZjc0dU5EdWJtbjFTb2diSjloaW9UWlRYenZ4aVNpNVU0cg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOenQxVUpFVmdNX3p1Z3lxQl9ySmdYVjYwdFNRLW14UlMxR1hCZV93REdtTzVUc3BLTnFhQTdndDhVQ25PLS1JdHNWa3RfdFJSaXVNajdlcFVqQktvQkhoUUdWc0JZUklkbmdRTE41a3g0ZTZNS1VjajNXM2VqUE5iMHd0bDlhSzhoeW5YR01PY1l1LXVHRThhX0hwUEM2dWVzTXc?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNN282M3NSaDF1R0g5RFpxMGRaaVFfTWdaSTZLX2owTm5yTmJ1VFlMRXdlX0ZWMEE2eFp2U2JoaUg1OVhfbTZkQndVRGczNElKLWFUV0lxS3VVMFAwM19WQzAwNC1kV21vQzBQd0tOQVNDRlQ4THcwZFVVR2dranV6elBPYlBNNlpHMFF4cUxKUzd3cHk2NDFMeWNVWUM2dUJVWGQw?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka taps Halozyme tech to cut injection volume in psoriasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMmUxblhCY3hoQWY3cVl2MDJMVzB1Sk9nYWc5SElCQmROYzVMOUZJdFJDTTItdzNWT2RvYnBoendINzZFWV9CMHpTQjl0Nm14OGpxZmFvdGduOUN5S1ZpcW9FSC02M1lsUEhuZ0kwUkNJVy1hQUcwT2pxNkF0b29XdnlmOTJqaC1FazlHRE52UFFINWlGRE1VMXFORFNoLW9ySTZwVnpTMmRzTy0xUlppcFdLMk92dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics (ORKA) Stock News, Page 4", "summary": "This page provides news and updates for Oruka Therapeutics (ORKA), a clinical-stage biotechnology company focused on novel biologics for chronic skin diseases. Recent news highlights preclinical data for ORKA-001 showing extended half-life, a $200 million private placement financ", "url": "https://www.stocktitan.net/news/ORKA/page-4.html", "source_name": "Stock Titan", "published_at": "2026-04-30T19:39:30", "published_display": "30 Apr 2026 19:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per Share | ORKA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdEdwYmNOd3lhUHhNSmdOY3pDMEpuTDNIUU8yWDAxeTFGTGFsaEJlYlZRcDVrTnhySmk3ZmNwUHY0dkFza1RaTk9kS3p0V1IxaGllcDRIa0c4Q21qY1BmcXFsWnRfdkF1VWtYYlhVbVlLNl9ZM3RLRU1hQ2UyQVdKYU10NWdHVHVFcnFXRnQtNElsWk83ZGpPaG9wR0JTbEJtSUJLbVRvNWFMSXhMNDhyeTdIMWhMYmhYNzZ0aXR0N1ZGNDZkNHQ1LWlsNA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics stock surges on positive psoriasis trial data By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPNnJHd3VJSUdDNW5GQTVxZ0VlcVF3YjZmbUFtN2RFZkpvdHJCNzNjREVKdnpwMGxqWllwZW4wdHB4WnpZaXZlbFRfT0RsbEJscV8wWDRhMTNuVjExNEgxaTVlUjJRWU80Skl1RHpEQ2R2cUE4aUE4M2xodVdLU0tqakJ2M1NOYVMwSU94NjdVekJ5RG0tUDhicnp6RXpkM2dLckVXVktpWFhaa0pFdmR3MV84bVVValIwSFo3czJ4WkdxaVU?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQaHR1aG1wZkZnTW9nNG9ZcW5xQmQ2UF9QNklkdEdJNm00Tnp4UlpzUHlfeHB5eGlVVWlvTk00V3diUVo3Z2tGejF0bUxoYkZ1RDlfRHNyemM2aHVScjRzRkVHajF0cHpmcGpLM2RtR0VxaEZYVVA5Vkc2VThyN2kwa2c0UEIxMVVQYVY2aUdxYVpYQmw2M1lRTWhDcTRDLVE4WXZnNDl1Ql9WQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial Result", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPSXJSRTFOOTdoUnZzRHA4WGcyNWFjX0pEeEJQWjFLTGZHRE5RbE1XV0dvVTlUNDdCaU9IeVpyY0JmS2taejZ0bklIUmp2eFIzU0lfOTZtczRyYmlLZzBEYk4wMF96RGNacl8wc1QydllNd2xQNURIdkZXTEtWS1A4R0ZvNG9PR2REVGo3V0VpZ09IQTFyYWRMSTYwYzRqR2hxMHNHbnc3bw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Oruka Therapeutics stock hits 52-week high at 64.72 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPNmwydXpCWGxPdTZSNnQ4X3g0bS10cVBQcmphb1huVDdnd21MZUhfeDJ6XzNQLUhWOW4yZ05tSmp3c295VnVIUExXcVJ3RjNlS2hZMkk2b3BfMkZRendXR3U4T1hBSzdqNnJ1SHJIcTMyVE4xaklSZTVUSnpscXp0VmxxOThyQlAyWnNXdWZ1SGc1Wm5hRk9YSW5SX0pyQ29HT0hrOEZaamFDSHduNGhV?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics\u2019 Psoriasis Drug Studies Have Lifted Its Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOYktON1lJZGEzelcyb1FIY1dKRTAxVDA1WnFrRjdCVUVyTXZ3M1FDQktoenVlNjgzYjFIRE05SndySlpiU1Z2bUtjZWtFWElRR1lJV19QdXFONGRUZ3RMMHhCNlN6a3RqckpDbHJCOE5tdlB1ellEWWpqV0d0V1Y3MWphYVZzXy0zZ1R3YWpRanpNc01LQjRKWVpnQ3dIRWVyM0E?oc=5", "source_name": "Barron's", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Does Oruka\u2019s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNcnY2aTRFc2hKblotbmlHbGlhYzJka0NnMVZPeGF6blBFZllYcWhvTGhZZFZHX1FVb191YW5NX2o3RFdoZ3I2dHJjTDZNTVNGZUdZZHB0MjZrYzVJY2xTZmN0Y3dVSEJOc1d3WGsyTUY0VVZJWlNYZFZwdXI0STJWZHczTmFtaC1pLVlBSHRDcU1ZMnFraUNBSEt3?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. Common Stock (ORKA) Stock Price Today: $83.04", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBOZ0Zmd2JpeThSc1BucTFvcU9rYXNpLW5XWmt0Z014bXBoT1RPTmdBYlVoTllKMXJwTHMwc1YzTGJqVkVtWTdiQW9xUDE4YUxhSGc4OHYyVQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:24:09+00:00", "published_display": "13 Jan 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORKA Stock Price and Chart \u2014 NASDAQ:ORKA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE85WlRMUTRucjNMTUtNM0FKb3pfamtiZVFaeFMwdDlnRkhucXJiblg2QTdmQVBDa0dPVTV4cWNXVi1aNGk4d0Fxa3JzNjdmdjI2eTEtay1LcXJDaUs4?oc=5", "source_name": "TradingView", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Announces $180 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOdkF2WmN3ZF8tNXVLVVctaGZSNDBqNEpxeTNreVN1S0Q5VWhGXzBMZnhGbFN4MU1qbHJPRnpzLVcyLUQ5RndNQWk4NUVSY2ZYWUNYeGQzZnZCN1BCZ1JsM0J5dExBWWhacExLVVlwdmsyUnI0U1R4bFFTNW02QzluUktwbmtyRW1Ma3piMVZtZHRNRVlwNHhWeGtNWGZfZ01aTUdqcy1oLTVORnJKZTE0V1V2ejJaMVlQeVlLSWl3WnhlSWFuTmJnSTF3?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-09-17T07:00:00+00:00", "published_display": "17 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million", "summary": "Oruka Therapeutics announced the completion of its merger with ARCA biopharma, Inc., and a $275 million private placement. The combined company will trade on Nasdaq under the ticker symbol \"ORKA\", with Samarth Kulkarni appointed Chairman of the Board. Oruka aims to advance its co", "url": "https://www.globenewswire.com/news-release/2024/09/03/2939515/0/en/Oruka-Therapeutics-Announces-Closing-of-Merger-with-ARCA-biopharma-and-Previously-Announced-Private-Placement-of-275-Million.html", "source_name": "GlobeNewswire", "published_at": "2024-09-03T07:00:00", "published_display": "03 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma, Oruka Therapeutics merger complete", "summary": "Arca Biopharma has announced the completion of its merger with Oruka Therapeutics Inc. This development follows a board approval for a 1-for-12 reverse stock split by Arca Biopharma prior to the merger. The article also touches upon related news in the biopharmaceutical sector, i", "url": "https://bizwest.com/2024/08/30/arca-biopharma-oruka-therapeutics-merger-complete/", "source_name": "BizWest", "published_at": "2024-08-30T12:36:37", "published_display": "30 Aug 2024 12:36", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split", "summary": "ARCA biopharma has announced the completion of its merger with Oruka Therapeutics and the implementation of a 1-for-12 reverse stock split. The combined entity will operate as Oruka Therapeutics, Inc., with its common stock trading on Nasdaq under the symbol \"ORKA\" starting Septe", "url": "https://www.globenewswire.com/news-release/2024/08/29/2938141/0/en/arca-biopharma-announces-completion-of-merger-with-oruka-therapeutics-and-implementation-of-reverse-stock-split.html", "source_name": "GlobeNewswire", "published_at": "2024-08-29T16:50:00", "published_display": "29 Aug 2024 16:50", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma board approves reverse stock split prior to Oruka merger", "summary": "Arca Biopharma's board of directors has approved a 1-for-12 reverse stock split. This action is being taken in advance of the drug-discovery company's upcoming merger with Oruka Therapeutics Inc. The full article content is for subscribers only.", "url": "https://bizwest.com/2024/08/26/arca-biopharma-board-approves-reverse-stock-split-prior-to-oruka-merger/", "source_name": "BizWest", "published_at": "2024-08-26T18:41:55", "published_display": "26 Aug 2024 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma Provides Update Regarding Special Dividend", "summary": "ARCA biopharma announced an updated special cash dividend of $1.613 per share, payable on August 28, 2024, to stockholders of record as of August 26, 2024, in connection with its upcoming merger with Oruka Therapeutics. Due to the dividend's size, Nasdaq has set August 29, 2024, ", "url": "https://www.globenewswire.com/news-release/2024/08/26/2935864/0/en/ARCA-biopharma-Provides-Update-Regarding-Special-Dividend-Amount-in-Connection-with-the-Proposed-Merger-with-Oruka-Therapeutics.html", "source_name": "GlobeNewswire", "published_at": "2024-08-26T01:52:05", "published_display": "26 Aug 2024 01:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics", "summary": "ARCA biopharma announced a 1-for-12 reverse stock split ahead of its merger with Oruka Therapeutics, effective September 3, 2024. Following the merger, ARCA will trade as Oruka Therapeutics, Inc. under the new ticker symbol \"ORKA\". The split will reduce outstanding shares and adj", "url": "https://finance.yahoo.com/news/arca-biopharma-announces-1-12-203000143.html", "source_name": "Market source", "published_at": "2024-08-23T04:23:09", "published_display": "23 Aug 2024 04:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma plans to sell off tech, IP as part of Oruka merger", "summary": "Arca Biopharma Inc. intends to divest assets related to its drug-discovery technology and intellectual property. This divestiture is a component of its anticipated reverse merger with Oruka Therapeutics Inc. The article is subscriber-only, limiting further details.", "url": "https://bizwest.com/2024/08/02/arca-biopharma-plans-to-sell-off-tech-ip-as-part-of-oruka-merger/", "source_name": "BizWest", "published_at": "2024-08-02T11:09:55", "published_display": "02 Aug 2024 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO", "summary": "Kahn Swick & Foti, LLC, led by former Attorney General Charles C. Foti, Jr., is investigating the proposed merger of ARCA biopharma, Inc. (ABIO) and Oruka Therapeutics. The investigation aims to determine if the merger is fair to ARCA shareholders, who are expected to own only 2.", "url": "https://markets.financialcontent.com/worldnow.insideindianabusiness/article/bizwire-2024-5-10-arca-biopharma-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-merger-of-arca-biopharma-inc-abio", "source_name": "FinancialContent", "published_at": "2024-05-10T18:34:00", "published_display": "10 May 2024 18:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma and Oruka Therapeutics Announce Merger Agreement", "summary": "ARCA biopharma and Oruka Therapeutics have announced a definitive merger agreement in an all-stock transaction. The combined company, to be named Oruka Therapeutics, Inc., will focus on advancing Oruka's biologics pipeline for chronic skin diseases, including ORKA-001 and ORKA-00", "url": "https://finance.yahoo.com/news/arca-biopharma-oruka-therapeutics-announce-113000527.html", "source_name": "Market source", "published_at": "2024-04-03T15:09:04", "published_display": "03 Apr 2024 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma stock ($ABIO) soars on merger news", "summary": "Arca Biopharma's stock surged after announcing a reverse merger with Oruka Therapeutics. The combined entity will operate as Oruka Therapeutics and secured $275 million in private financing to fund operations through 2027. This merger aims to advance Oruka's therapies for chronic", "url": "https://invezz.com/news/2024/04/03/arca-biopharma-stock-abio-soars-on-merger-new/", "source_name": "Invezz", "published_at": "2024-04-03T11:38:00", "published_display": "03 Apr 2024 11:38", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details", "summary": "ARCA Biopharma Inc. (NASDAQ: ABIO) is merging with Oruka Therapeutics, a private biotechnology company, in an all-stock transaction. The combined entity, to be named Oruka Therapeutics Inc. and trade under \"ORKA,\" will focus on advancing Oruka\u2019s pipeline for chronic skin diseases", "url": "https://finance.yahoo.com/news/small-cap-arca-biopharma-stock-160056479.html", "source_name": "Market source", "published_at": "2024-04-03T09:09:23", "published_display": "03 Apr 2024 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors funnel $275 million into Paragon Therapeutics-spinout", "summary": "Investors have committed $275 million to Oruka Therapeutics, a new biotech company specializing in treatments for psoriasis and psoriatic arthritis that could be administered as infrequently as once or twice a year. Oruka Therapeutics was launched through a reverse merger with AR", "url": "https://www.statnews.com/2024/04/03/investors-funnel-275-million-into-paragon-therapeutics-spinout/", "source_name": "STAT", "published_at": "2024-04-03T04:23:09", "published_display": "03 Apr 2024 04:23", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5Gd0pTdnBBVXZ1eXhxeklJYmJLaTFGZDRaeUlBNmxLUTFmNm5nQV9rcDRtR0lLaHQtT2taUklmajlHM05GekRKeGcxdnJ5OF9aNHc?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-18T00:36:00+00:00", "published_display": "18 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdDZLMUZzM1ViXzJfUWU2LXVUNHIyd0l0Rkc1YXBOc1NnajNGVEVvQTBXWDdVemhIWElZcWpzNDEzdDNvWE1BTmZQVUMxdENwWGdrbE5iWnJ0aGlNeFc2NmpDTU1XelVsREY5U1pLUS1id25HRUtmc1R0NEQ0Vko1eU5Vanc4RXgyUVlJYkJPMkFKcUdPN0RpckYyVTJZektf?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T14:51:00+00:00", "published_display": "17 Jul 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Oruka Therapeutics Inc For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPY29tYVZyT0FXejJ5LU1nWWptU2NGNFh4UnFybDc3aU9Bb2MxTEZKS0Q2bUpFdkdDODlEQXBob2FvVm1OVzdUMmV2UjRBVG9wZnlCMU82a19GNGtlSUJ5b0hfa28yLUVfWElia1ZqQUZXOVR1SFpqNGNIWXR5UnFWT2sxN3pNLTZ4S3ZiUlFQOHdySEtsSDNwVWg3TjZoaGJNQ3lZRg?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T00:52:17+00:00", "published_display": "16 Jul 2026 00:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPY0pYZlQ0UzV1V3Jza3hzeUc5cTZCeERmVVVuWDRzdS1sNGpmT3NTUEx0ZExLbUIyMjhNYmgtSnJNdi11Qk9uYzVTRWhlYTRBTW1TbGRkaVhZWjdNSEVzbGx2VFlKRjJ5WFRkRUJfYnBGRjdFb2JPLWFMNllDUm9YZ1dWQUJUSk9aRXpZOUg0SnM0aTQ1aExpNWc4YWJqaXhRRURQLTdqWF9Oc1FwV2EzSWZuTUV6eFJSU3BGTmVyc2YxenFL?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T23:47:40+00:00", "published_display": "15 Jul 2026 23:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oruka-therapeutics-insider-sold-shares-212226470.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:22:26+00:00", "published_display": "13 Jul 2026 21:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Oruka Therapeutics (ORKA) Russell Index Shift Toward Small-Cap Growth Benchmarks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUURjSjhESGVzU3hCOXZSTTR2YTNQMExsR3Z0cjFaZlBiWUlPMTgwSGFZV083RndCcHROZHJhNmI1TnlWMVBNVmtxQjM2MkcwM1RBeGNMbUR4OVpLYmYzN0x4N2c0NVpSUnd0anlLQWVuOHBNclBrb29USG1qZ3pvMzZVMVUwX2toMGc3TGhrUDFRR3hCbzRhRjQ3bGtIaTZoY2ROMjdMQlZLQjdjVlpwY09jSkxlcmZYZWpjaHN2UGJzaXpaQWJRQmtRT0d6bnJKcFgzR2FveUlmQ01EU0NEUFlOazlwZjjSAewBQVVfeXFMTzU1MGRHS0Rxd3NvWTRNTkloTzdKRzJGNFN3M3JCTzJaS05GLXBrYWNYdGhfdnMwR2dzamlfT3FUdGRNSnNtd3VzYmE1UGgxOGxSdm5RcnRrbWZlWmNlSEtOVm1uTlRaN0JicmZ4cERYLUtzeHBCdE5Db3UtYzNlS21qaGk2dFNTWG9OVW1ibjRWT2sxZm9pQnN1TmpxeHFWSWxiUERROXUteERPY1JBWEhfMERldXVFQXFDcE45RFdid0FzcE1QQ0hNMGVzVWhNUGJSdV85U1ZRamRxVDlVOVMyNEZvX2JfenlsVUY?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T01:05:46+00:00", "published_display": "10 Jul 2026 01:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oruka-therapeutics-insider-sold-shares-082527388.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:25:27+00:00", "published_display": "02 Jul 2026 08:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/h-c-wainwright-keeps-buy-212333523.html", "source_name": "Insider Monkey", "published_at": "2026-07-01T21:23:33+00:00", "published_display": "01 Jul 2026 21:23", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/oruka-therapeutics-h2-orka-001-152348961.html", "source_name": "MT Newswires", "published_at": "2026-07-01T15:23:48+00:00", "published_display": "01 Jul 2026 15:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Adjusts Price Target on Oruka Therapeutics to $130 From $100, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-price-target-oruka-144342183.html", "source_name": "MT Newswires", "published_at": "2026-07-01T14:43:42+00:00", "published_display": "01 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPVm9fWkpWZlNHU2ozLUJwcU1NamYtRkVjb1RvMktGUXBaN0hSNVRPZ0Q4M2NpeGNucGpQakRxM0w3Yng5MmpzdkNnanBqTjVSellBb0pocVJqQ0tDa1RsQjFPV0xwMHdjQkVjMWtiaDVxakFaRXkteVZ5c3hsUHBTWVVHTzhMTDlNRkdScmJ1S1RORWFTRjhIN3R4ZnNjZHp4ZXdRUElVTHVrZFhySVpFRVl3ekg4aFlCWFBXclFQemRCWnh5Z2lpeUhDTQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/650f4e3a-936a-39f2-bc9a-a6fc1616bb65/oruka-therapeutics%27-head-of.html", "source_name": "Motley Fool", "published_at": "2026-06-24T21:44:01+00:00", "published_display": "24 Jun 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Oruka Therapeutics Inc For: 22 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOREo2aHFKSEhjSzNFX2tKZVI4WFhvVXprNUZhNEpDa3RhcFRiU0wxMjZKSzVaeWpZbmZQWDdYME9CLUtvTjcyM1BSWENnS3ctNF9DQUp0WmRqek5pdF9zalpPdi16T2hPZjdGXy1UT3JSYlNMRnJfNVcxeG14ZXBNVDIwZjA4a0dJU3c1US1ReG9ralFQOWdkZnhNclZrR1IyN1hmQQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics SVP Arjun Agarwal sells $128,468 in ORKA stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOZDE0cldyV003Mk5LLXBuYldWOFFWbVZnSm5Uek1qTWppQmVIMUs0cEtaQzB5dDU4eFgzZHdocEZLYVBNT1FybzZabzhmSlJJc2NzMUU1bjJHazhtYXRJU1dZM0FjMVAzaWJOZldWYzdyelJac3RSTHQxTThIQkk4WFVKVEZBMTVQRElTZnlfYTY0ajFoZ3lsSW1YeWsxTDQzMnd5LXRsd1VPN0p3OTI2aVZDS3N4ZnY0NExDOHNiVG41cEpyRFJn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Arjun Agarwal Sells Shares of Oruka Therapeutics I", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPOHhldll2T1l4Ym9zWkhtQi1ET2huWU9zbWFiUkxGRUJvd2FOVzlvVWJUeUN1N3dCS0p5c0Y2bEFsbWlicEs0WFJaVlRBb0V3MllfNnZka29vQ0JrMkw0akFva2o0NV9wNVpUOGplejhQdzZ5UzZtY0VuVFd0dTRQeGFtV2U4cUdWTzI5dHcwdWhNeGNESnRDREMtNFRid0YyOHRWYmhPNTFOTHo3VzNwOUJpdlhmYlJxTEg5M1I5YkxfNGxIblBSRDhJTTE4TjBOZUw0OHRfdE9yT1NSZmw5aU9zYw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOSnJXLW05bjhaNFNtZTExWmptRkktcGxIblZVenpyekpQYXo5Rm9mdlNYNjZScUZ3ZjBYNmFDY2tzMXVrUnlIVU1EcEpFY04zSGNuNU9tQlVvTDNNaDdHMHhzYjRNMFpFRENPeXVaUEZuTDkzNFRsVU9QWWpPalZZRFNiM2MwY2FMV25TUHRoUDFfa3BqajlibVl0a1NLWGJINHpN?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPRkEyYXBaUnhGbi1lWGZUQ2VpQkEwMEhjRUNZT2NJdzBsNXJGSFFvVnhxMEh6Vll2S0lJN0R4ZEpuYllXWUppUHUyRnNVMjZkTFhaMWpfZ3FHZWpuNzNmNnRuUVZscjJNaFBwenEzQ2ZVQm9iM1lfYmNSM2RGd2VTZjN3Y1AxRC1faEJDSXdFbHBhUzY2R21oRldrWmhxaEpT?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Announces Closing of Merger with ARCA", "summary": "Oruka Therapeutics announced the completion of its merger with ARCA biopharma and a $275 million private placement. The combined company, now trading on Nasdaq under \"ORKA\", aims to advance pipeline programs ORKA-001 and ORKA-002 for chronic skin diseases. Dr. Samarth Kulkarni ha", "url": "https://www.globenewswire.com/news-release/2024/09/03/2939515/0/en/oruka-therapeutics-announces-closing-of-merger-with-arca-biopharma-and-previously-announced-private-placement-of-275-million.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T19:09:58", "published_display": "13 May 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOdnRPaC1McTZUT1oyVDd1TWlmV3RlZlhRMHZiZkpYZUgwS2pBYmZjcjk2THV2SlItT1VHTDVTWWNJYmpQaGVhREMzaDh3cnZrQkJpbVJRUU1SMEpPN1FyMDlJbWE1XzJaUGVtWWNBQ2lsTWdNckFaaTFabzFCWGpXQ3ZWWksxY0hVZHJaWEpWcDdtN1BBb2xWcDh6NkFSdmJkR3ZGdmFMbm5MWnZRVGJPU2pMSlg5SGZtc1d1YzBBc2dYWTh0LTZzOGhvSDhEX3F6WWtSWGVjZjc0dU5EdWJtbjFTb2diSjloaW9UWlRYenZ4aVNpNVU0cg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOenQxVUpFVmdNX3p1Z3lxQl9ySmdYVjYwdFNRLW14UlMxR1hCZV93REdtTzVUc3BLTnFhQTdndDhVQ25PLS1JdHNWa3RfdFJSaXVNajdlcFVqQktvQkhoUUdWc0JZUklkbmdRTE41a3g0ZTZNS1VjajNXM2VqUE5iMHd0bDlhSzhoeW5YR01PY1l1LXVHRThhX0hwUEM2dWVzTXc?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNN282M3NSaDF1R0g5RFpxMGRaaVFfTWdaSTZLX2owTm5yTmJ1VFlMRXdlX0ZWMEE2eFp2U2JoaUg1OVhfbTZkQndVRGczNElKLWFUV0lxS3VVMFAwM19WQzAwNC1kV21vQzBQd0tOQVNDRlQ4THcwZFVVR2dranV6elBPYlBNNlpHMFF4cUxKUzd3cHk2NDFMeWNVWUM2dUJVWGQw?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka taps Halozyme tech to cut injection volume in psoriasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMmUxblhCY3hoQWY3cVl2MDJMVzB1Sk9nYWc5SElCQmROYzVMOUZJdFJDTTItdzNWT2RvYnBoendINzZFWV9CMHpTQjl0Nm14OGpxZmFvdGduOUN5S1ZpcW9FSC02M1lsUEhuZ0kwUkNJVy1hQUcwT2pxNkF0b29XdnlmOTJqaC1FazlHRE52UFFINWlGRE1VMXFORFNoLW9ySTZwVnpTMmRzTy0xUlppcFdLMk92dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics (ORKA) Stock News, Page 4", "summary": "This page provides news and updates for Oruka Therapeutics (ORKA), a clinical-stage biotechnology company focused on novel biologics for chronic skin diseases. Recent news highlights preclinical data for ORKA-001 showing extended half-life, a $200 million private placement financ", "url": "https://www.stocktitan.net/news/ORKA/page-4.html", "source_name": "Stock Titan", "published_at": "2026-04-30T19:39:30", "published_display": "30 Apr 2026 19:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per Share | ORKA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdEdwYmNOd3lhUHhNSmdOY3pDMEpuTDNIUU8yWDAxeTFGTGFsaEJlYlZRcDVrTnhySmk3ZmNwUHY0dkFza1RaTk9kS3p0V1IxaGllcDRIa0c4Q21qY1BmcXFsWnRfdkF1VWtYYlhVbVlLNl9ZM3RLRU1hQ2UyQVdKYU10NWdHVHVFcnFXRnQtNElsWk83ZGpPaG9wR0JTbEJtSUJLbVRvNWFMSXhMNDhyeTdIMWhMYmhYNzZ0aXR0N1ZGNDZkNHQ1LWlsNA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics stock surges on positive psoriasis trial data By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPNnJHd3VJSUdDNW5GQTVxZ0VlcVF3YjZmbUFtN2RFZkpvdHJCNzNjREVKdnpwMGxqWllwZW4wdHB4WnpZaXZlbFRfT0RsbEJscV8wWDRhMTNuVjExNEgxaTVlUjJRWU80Skl1RHpEQ2R2cUE4aUE4M2xodVdLU0tqakJ2M1NOYVMwSU94NjdVekJ5RG0tUDhicnp6RXpkM2dLckVXVktpWFhaa0pFdmR3MV84bVVValIwSFo3czJ4WkdxaVU?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQaHR1aG1wZkZnTW9nNG9ZcW5xQmQ2UF9QNklkdEdJNm00Tnp4UlpzUHlfeHB5eGlVVWlvTk00V3diUVo3Z2tGejF0bUxoYkZ1RDlfRHNyemM2aHVScjRzRkVHajF0cHpmcGpLM2RtR0VxaEZYVVA5Vkc2VThyN2kwa2c0UEIxMVVQYVY2aUdxYVpYQmw2M1lRTWhDcTRDLVE4WXZnNDl1Ql9WQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial Result", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPSXJSRTFOOTdoUnZzRHA4WGcyNWFjX0pEeEJQWjFLTGZHRE5RbE1XV0dvVTlUNDdCaU9IeVpyY0JmS2taejZ0bklIUmp2eFIzU0lfOTZtczRyYmlLZzBEYk4wMF96RGNacl8wc1QydllNd2xQNURIdkZXTEtWS1A4R0ZvNG9PR2REVGo3V0VpZ09IQTFyYWRMSTYwYzRqR2hxMHNHbnc3bw?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics stock hits 52-week high at 64.72 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPNmwydXpCWGxPdTZSNnQ4X3g0bS10cVBQcmphb1huVDdnd21MZUhfeDJ6XzNQLUhWOW4yZ05tSmp3c295VnVIUExXcVJ3RjNlS2hZMkk2b3BfMkZRendXR3U4T1hBSzdqNnJ1SHJIcTMyVE4xaklSZTVUSnpscXp0VmxxOThyQlAyWnNXdWZ1SGc1Wm5hRk9YSW5SX0pyQ29HT0hrOEZaamFDSHduNGhV?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics\u2019 Psoriasis Drug Studies Have Lifted Its Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOYktON1lJZGEzelcyb1FIY1dKRTAxVDA1WnFrRjdCVUVyTXZ3M1FDQktoenVlNjgzYjFIRE05SndySlpiU1Z2bUtjZWtFWElRR1lJV19QdXFONGRUZ3RMMHhCNlN6a3RqckpDbHJCOE5tdlB1ellEWWpqV0d0V1Y3MWphYVZzXy0zZ1R3YWpRanpNc01LQjRKWVpnQ3dIRWVyM0E?oc=5", "source_name": "Barron's", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Oruka\u2019s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNcnY2aTRFc2hKblotbmlHbGlhYzJka0NnMVZPeGF6blBFZllYcWhvTGhZZFZHX1FVb191YW5NX2o3RFdoZ3I2dHJjTDZNTVNGZUdZZHB0MjZrYzVJY2xTZmN0Y3dVSEJOc1d3WGsyTUY0VVZJWlNYZFZwdXI0STJWZHczTmFtaC1pLVlBSHRDcU1ZMnFraUNBSEt3?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics, Inc. Common Stock (ORKA) Stock Price Today: $83.04", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBOZ0Zmd2JpeThSc1BucTFvcU9rYXNpLW5XWmt0Z014bXBoT1RPTmdBYlVoTllKMXJwTHMwc1YzTGJqVkVtWTdiQW9xUDE4YUxhSGc4OHYyVQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:24:09+00:00", "published_display": "13 Jan 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORKA Stock Price and Chart \u2014 NASDAQ:ORKA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE85WlRMUTRucjNMTUtNM0FKb3pfamtiZVFaeFMwdDlnRkhucXJiblg2QTdmQVBDa0dPVTV4cWNXVi1aNGk4d0Fxa3JzNjdmdjI2eTEtay1LcXJDaUs4?oc=5", "source_name": "TradingView", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Announces $180 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOdkF2WmN3ZF8tNXVLVVctaGZSNDBqNEpxeTNreVN1S0Q5VWhGXzBMZnhGbFN4MU1qbHJPRnpzLVcyLUQ5RndNQWk4NUVSY2ZYWUNYeGQzZnZCN1BCZ1JsM0J5dExBWWhacExLVVlwdmsyUnI0U1R4bFFTNW02QzluUktwbmtyRW1Ma3piMVZtZHRNRVlwNHhWeGtNWGZfZ01aTUdqcy1oLTVORnJKZTE0V1V2ejJaMVlQeVlLSWl3WnhlSWFuTmJnSTF3?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-09-17T07:00:00+00:00", "published_display": "17 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million", "summary": "Oruka Therapeutics announced the completion of its merger with ARCA biopharma, Inc., and a $275 million private placement. The combined company will trade on Nasdaq under the ticker symbol \"ORKA\", with Samarth Kulkarni appointed Chairman of the Board. Oruka aims to advance its co", "url": "https://www.globenewswire.com/news-release/2024/09/03/2939515/0/en/Oruka-Therapeutics-Announces-Closing-of-Merger-with-ARCA-biopharma-and-Previously-Announced-Private-Placement-of-275-Million.html", "source_name": "GlobeNewswire", "published_at": "2024-09-03T07:00:00", "published_display": "03 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma, Oruka Therapeutics merger complete", "summary": "Arca Biopharma has announced the completion of its merger with Oruka Therapeutics Inc. This development follows a board approval for a 1-for-12 reverse stock split by Arca Biopharma prior to the merger. The article also touches upon related news in the biopharmaceutical sector, i", "url": "https://bizwest.com/2024/08/30/arca-biopharma-oruka-therapeutics-merger-complete/", "source_name": "BizWest", "published_at": "2024-08-30T12:36:37", "published_display": "30 Aug 2024 12:36", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split", "summary": "ARCA biopharma has announced the completion of its merger with Oruka Therapeutics and the implementation of a 1-for-12 reverse stock split. The combined entity will operate as Oruka Therapeutics, Inc., with its common stock trading on Nasdaq under the symbol \"ORKA\" starting Septe", "url": "https://www.globenewswire.com/news-release/2024/08/29/2938141/0/en/arca-biopharma-announces-completion-of-merger-with-oruka-therapeutics-and-implementation-of-reverse-stock-split.html", "source_name": "GlobeNewswire", "published_at": "2024-08-29T16:50:00", "published_display": "29 Aug 2024 16:50", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma board approves reverse stock split prior to Oruka merger", "summary": "Arca Biopharma's board of directors has approved a 1-for-12 reverse stock split. This action is being taken in advance of the drug-discovery company's upcoming merger with Oruka Therapeutics Inc. The full article content is for subscribers only.", "url": "https://bizwest.com/2024/08/26/arca-biopharma-board-approves-reverse-stock-split-prior-to-oruka-merger/", "source_name": "BizWest", "published_at": "2024-08-26T18:41:55", "published_display": "26 Aug 2024 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma Provides Update Regarding Special Dividend", "summary": "ARCA biopharma announced an updated special cash dividend of $1.613 per share, payable on August 28, 2024, to stockholders of record as of August 26, 2024, in connection with its upcoming merger with Oruka Therapeutics. Due to the dividend's size, Nasdaq has set August 29, 2024, ", "url": "https://www.globenewswire.com/news-release/2024/08/26/2935864/0/en/ARCA-biopharma-Provides-Update-Regarding-Special-Dividend-Amount-in-Connection-with-the-Proposed-Merger-with-Oruka-Therapeutics.html", "source_name": "GlobeNewswire", "published_at": "2024-08-26T01:52:05", "published_display": "26 Aug 2024 01:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics", "summary": "ARCA biopharma announced a 1-for-12 reverse stock split ahead of its merger with Oruka Therapeutics, effective September 3, 2024. Following the merger, ARCA will trade as Oruka Therapeutics, Inc. under the new ticker symbol \"ORKA\". The split will reduce outstanding shares and adj", "url": "https://finance.yahoo.com/news/arca-biopharma-announces-1-12-203000143.html", "source_name": "Market source", "published_at": "2024-08-23T04:23:09", "published_display": "23 Aug 2024 04:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma plans to sell off tech, IP as part of Oruka merger", "summary": "Arca Biopharma Inc. intends to divest assets related to its drug-discovery technology and intellectual property. This divestiture is a component of its anticipated reverse merger with Oruka Therapeutics Inc. The article is subscriber-only, limiting further details.", "url": "https://bizwest.com/2024/08/02/arca-biopharma-plans-to-sell-off-tech-ip-as-part-of-oruka-merger/", "source_name": "BizWest", "published_at": "2024-08-02T11:09:55", "published_display": "02 Aug 2024 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO", "summary": "Kahn Swick & Foti, LLC, led by former Attorney General Charles C. Foti, Jr., is investigating the proposed merger of ARCA biopharma, Inc. (ABIO) and Oruka Therapeutics. The investigation aims to determine if the merger is fair to ARCA shareholders, who are expected to own only 2.", "url": "https://markets.financialcontent.com/worldnow.insideindianabusiness/article/bizwire-2024-5-10-arca-biopharma-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-and-foti-llc-investigates-merger-of-arca-biopharma-inc-abio", "source_name": "FinancialContent", "published_at": "2024-05-10T18:34:00", "published_display": "10 May 2024 18:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCA biopharma and Oruka Therapeutics Announce Merger Agreement", "summary": "ARCA biopharma and Oruka Therapeutics have announced a definitive merger agreement in an all-stock transaction. The combined company, to be named Oruka Therapeutics, Inc., will focus on advancing Oruka's biologics pipeline for chronic skin diseases, including ORKA-001 and ORKA-00", "url": "https://finance.yahoo.com/news/arca-biopharma-oruka-therapeutics-announce-113000527.html", "source_name": "Market source", "published_at": "2024-04-03T15:09:04", "published_display": "03 Apr 2024 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arca Biopharma stock ($ABIO) soars on merger news", "summary": "Arca Biopharma's stock surged after announcing a reverse merger with Oruka Therapeutics. The combined entity will operate as Oruka Therapeutics and secured $275 million in private financing to fund operations through 2027. This merger aims to advance Oruka's therapies for chronic", "url": "https://invezz.com/news/2024/04/03/arca-biopharma-stock-abio-soars-on-merger-new/", "source_name": "Invezz", "published_at": "2024-04-03T11:38:00", "published_display": "03 Apr 2024 11:38", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details", "summary": "ARCA Biopharma Inc. (NASDAQ: ABIO) is merging with Oruka Therapeutics, a private biotechnology company, in an all-stock transaction. The combined entity, to be named Oruka Therapeutics Inc. and trade under \"ORKA,\" will focus on advancing Oruka\u2019s pipeline for chronic skin diseases", "url": "https://finance.yahoo.com/news/small-cap-arca-biopharma-stock-160056479.html", "source_name": "Market source", "published_at": "2024-04-03T09:09:23", "published_display": "03 Apr 2024 09:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors funnel $275 million into Paragon Therapeutics-spinout", "summary": "Investors have committed $275 million to Oruka Therapeutics, a new biotech company specializing in treatments for psoriasis and psoriatic arthritis that could be administered as infrequently as once or twice a year. Oruka Therapeutics was launched through a reverse merger with AR", "url": "https://www.statnews.com/2024/04/03/investors-funnel-275-million-into-paragon-therapeutics-spinout/", "source_name": "STAT", "published_at": "2024-04-03T04:23:09", "published_display": "03 Apr 2024 04:23", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 54, "sentiment_summary": {"positive": 15, "negative": 4, "neutral": 35, "score": 55, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "deals", "label": "Deals and strategy", "weight": 7.15, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 92.7, "latest_week": "2026-07-17", "one_week_move": 6.8, "four_week_move": 28.1, "twelve_week_move": 34.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.991416, "market_dynamics_buy_signal": false, "relative_strength": 115.650464, "fair_value_gap": 275.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.2022, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.8% over one week, +28.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "GlobeNewswire", "count": 6}, {"label": "MT Newswires", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "BizWest", "count": 3}, {"label": "Quiver Quantitative", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Deals and strategy", "count": 13}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.8% over one week, +28.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ"}], "updated_at": "2026-07-22T03:47:20.301853+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}